Companies · Pharmaceuticals
NAPLES · Pharmaceuticals
Diligence memoA one-page analyst read on Doza Investments - Relox Medical, L.P. — recommendation, valuation, rhythm, risks.→Doza Investments - Relox Medical, L.P. looks under-valued against its niche peers and is active on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Doza Investments - Relox Medical, L.P. is one of 1613 Pharmaceuticals companies tracked from NAPLES. By capital raised it ranks in the long tail (ahead of 31% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 31% of sector peers (real $). Modeled value above 7% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $2.7M | — | $13.3M | $4.5M | 90% |
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| THOMAS ANTHONY AMENDOLA | — | 1 other | — |
Doza Investments - Relox Medical, L.P. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Gate Science Inc. | Pharmaceuticals | Seed | $2.6M | $1.7M | same sector · same stage |
| TheraVasc Inc. | Pharmaceuticals | Seed | $2.6M | $13.3M | same sector · same stage |
| Xtresse, Llc | Pharmaceuticals | Seed | $2.7M | $6.5M | same sector · same stage |
| Nomocan Pharmaceuticals Llc | Pharmaceuticals | Seed | $2.7M | $3.4M | same sector · same stage |
| Earth Science Tech, Inc. | Pharmaceuticals | Seed | $2.8M | $7.8M | same sector · same stage |
| Aclipse Therapeutics LLC | Pharmaceuticals | Seed | $2.5M | $4.2M | same sector · same stage |
| ImmunoPrecise Antibodies Ltd. | Pharmaceuticals | Seed | $2.5M | $9.3M | same sector · same stage |
| Mayne Pharma Group Ltd | Pharmaceuticals | Seed | $2.8M | $5.4M | same sector · same stage |
See where Doza Investments - Relox Medical, L.P. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Doza Investments - Relox Medical, L.P., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.